Arcadia Biosciences (RKDA) Reaches $0.46 52 Week Low, Ecor1 Capital Has Lowered Its Agios Pharmaceuticals (AGIO) Stake

July 5, 2017 - By Migdalia James

Ecor1 Capital Llc decreased Agios Pharmaceuticals Inc (AGIO) stake by 88.35% reported in 2016Q4 SEC filing. Ecor1 Capital Llc sold 176,700 shares as Agios Pharmaceuticals Inc (AGIO)’s stock declined 9.11%. The Ecor1 Capital Llc holds 23,300 shares with $972,000 value, down from 200,000 last quarter. Agios Pharmaceuticals Inc now has $2.57 billion valuation. The stock rose 0.86% or $0.45 reaching $52.63. About 171,562 shares traded. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since July 5, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

The stock of Arcadia Biosciences Inc (NASDAQ:RKDA) hit a new 52-week low and has $0.43 target or 7.00% below today’s $0.46 share price. The 9 months bearish chart indicates high risk for the $21.47M company. The 1-year low was reported on Jul, 5 by Barchart.com. If the $0.43 price target is reached, the company will be worth $1.50M less. About 21,855 shares traded. Arcadia Biosciences Inc (NASDAQ:RKDA) has declined 43.32% since July 5, 2016 and is downtrending. It has underperformed by 60.02% the S&P500.

Arcadia Biosciences, Inc. is an agricultural biotechnology trait company. The company has market cap of $21.47 million. The Firm develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It currently has negative earnings. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market.

Investors sentiment decreased to 1.1 in 2016 Q4. Its down 0.62, from 1.72 in 2016Q3. It dived, as 23 investors sold AGIO shares while 45 reduced holdings. 19 funds opened positions while 56 raised stakes. 37.23 million shares or 3.48% more from 35.97 million shares in 2016Q3 were reported. Fiera reported 57,615 shares. Pacad Inv, British Columbia – Canada-based fund reported 2,200 shares. Alliancebernstein Ltd Partnership owns 18,692 shares for 0% of their portfolio. Employees Retirement Association Of Colorado stated it has 6,194 shares. Legal General Pcl has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Cap Investors reported 0.01% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Moreover, Ballentine Partners Limited Liability Corporation has 0.03% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 9,709 shares. Ohio-based Victory Capital Mngmt has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Redmile Grp Inc Limited Liability Corp owns 738,451 shares or 2.66% of their US portfolio. Tarbox Gru invested in 16 shares or 0% of the stock. Allianz Asset Management Ag, Germany-based fund reported 11,074 shares. Capital Guardian holds 0.27% or 816,200 shares in its portfolio. Massachusetts-based Eventide Asset Management Ltd has invested 0.82% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). State Street Corp, a Massachusetts-based fund reported 1.24M shares. Ny State Common Retirement Fund has 68,720 shares for 0% of their portfolio.

Among 13 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Agios Pharmaceuticals had 24 analyst reports since July 23, 2015 according to SRatingsIntel. Credit Suisse maintained the shares of AGIO in report on Wednesday, May 18 with “Outperform” rating. BTIG Research initiated the shares of AGIO in report on Friday, August 19 with “Neutral” rating. The rating was maintained by TH Capital with “Neutral” on Monday, November 9. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has “Market Perform” rating given on Monday, December 7 by Leerink Swann. The company was maintained on Wednesday, May 18 by Suntrust Robinson. The stock has “Neutral” rating by Janney Capital on Monday, June 26. The rating was maintained by Roth Capital on Monday, November 9 with “Neutral”. On Wednesday, March 30 the stock rating was initiated by SunTrust with “Buy”. As per Tuesday, January 17, the company rating was upgraded by Oppenheimer. JP Morgan upgraded the stock to “Overweight” rating in Monday, June 13 report.

Since February 16, 2017, it had 0 insider purchases, and 13 sales for $22.46 million activity. Cantley Lewis Clayton Jr. sold $108,132 worth of stock or 2,036 shares. Shares for $150,060 were sold by Schenkein David P. Shares for $12.00M were sold by NELSEN ROBERT on Monday, February 27. Biller Scott also sold $124,532 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Monday, April 3.